Islet microRNAs in health and type-2 diabetes

被引:27
|
作者
Wendt, Anna
Esguerra, Jonathan L. S.
Eliasson, Lena [1 ]
机构
[1] Lund Univ, Dept Clin Sci Malmo, Diabet Ctr, Islet Cell Exocytosis, Malmo, Sweden
基金
欧盟地平线“2020”; 瑞典研究理事会;
关键词
BETA-CELL FUNCTION; INSULIN-SECRETION; GLUCOSE; EXPRESSION; CLUSTER; REGULATORS; MIR-375; GENES;
D O I
10.1016/j.coph.2018.08.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Failure of the beta-cell to secrete enough insulin is a major contributing factor in the pathogenesis of type-2 diabetes (T2D). MicroRNAs provide an extra layer in the regulation of protein expression, and are thus involved in beta-cell compensation during development of the disease. In this review, we discuss how microRNAs can regulate their target protein expression and phenotypic output, present the status of nutritional regulation of microRNA expression, and summarize work on microRNA expression in human islets. In conclusion, current data lend support to microRNAs being essential regulators of insulin secretion. Future work will describe microRNAs in alpha-cell function, details of the microRNA mRNA network, and possibilities to use microRNAs as biomarkers and in therapeutic treatment of T2D and complications.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [1] ISLET AMYLOID AND TYPE-2 DIABETES
    CLARK, A
    DIABETIC MEDICINE, 1989, 6 (07) : 561 - 567
  • [2] ISLET AMYLOID - AN ENIGMA OF TYPE-2 DIABETES
    CLARK, A
    DIABETES-METABOLISM REVIEWS, 1992, 8 (02): : 117 - 132
  • [3] ISLET AMYLOID POLYPEPTIDE - THE CAUSE OF TYPE-2 DIABETES
    BRETHERTONWATT, D
    BLOOM, SR
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1991, 2 (06): : 203 - 206
  • [4] ISLET AMYLOID AND TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES
    CLARK, A
    SOUTH AFRICAN MEDICAL JOURNAL, 1990, : 7 - 11
  • [5] ISLET AMYLOID POLYPEPTIDE - HEN OR EGG IN TYPE-2 DIABETES PATHOGENESIS
    BETSHOLTZ, C
    CHRISTMANSON, L
    GEBREMEDHIN, S
    WESTERMARK, P
    ACTA ONCOLOGICA, 1993, 32 (02) : 149 - 154
  • [6] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Louise A. Scrocchi
    Yan Chen
    Feng Wang
    Kyung Han
    Katherine Ha
    Ling Wu
    Paul E. Fraser
    Letters in Peptide Science, 2003, 10 : 545 - 551
  • [7] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Scrocchi, LA
    Chen, Y
    Wang, F
    Han, K
    Ha, K
    Wu, L
    Fraser, PE
    LETTERS IN PEPTIDE SCIENCE, 2003, 10 (5-6): : 545 - 551
  • [8] DEMONSTRATION OF ISLET-CELL AND NON-ISLET CELL PANCREATIC AUTOIMMUNITY IN TYPE-2 DIABETES
    ARMSTRONG, E
    JOHNSTON, CF
    HADDEN, DR
    BUCHANAN, KD
    REGULATORY PEPTIDES, 1988, 22 (04) : 389 - 389
  • [9] ISLET PATHOLOGY AND THE PATHOGENESIS OF TYPE-1 AND TYPE-2 DIABETES-MELLITUS REVISITED
    KLOPPEL, G
    LOHR, M
    HABICH, K
    OBERHOLZER, M
    HEITZ, PU
    SURVEY AND SYNTHESIS OF PATHOLOGY RESEARCH, 1985, 4 (02): : 110 - 125
  • [10] Islet autoantibodies in type-1 or type-2 diabetes in four US racial groups
    Marker, JD
    Chopra, M
    Ten, S
    Su, K
    Zeidler, A
    Raskin, P
    Rappaport, R
    Schatz, D
    Vargas, A
    Malone, J
    Bode, B
    Krischer, J
    MacLaren, NK
    DIABETES, 2001, 50 : A262 - A262